Riitta Kekomäki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Riitta Kekomäki has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
K. Javela
Finnish Red Cross Blood Transfusion Service, Helsinki, Finland
3 shared publicationsK Teramo
2 shared publicationsKaija Javela
Finnish Red Cross Blood Transfusion Service, Helsinki
2 shared publicationsA Lindbom
Finnish Red Cross Blood Transfusion Service, Kivihaantie 7, Helsinki, Finland
1 shared publicationE Vahtera
Finnish Red Cross Blood Transfusion Service, Kivihaantie 7, Helsinki, Finland
1 shared publicationE. Ikkala
Finnish Red Cross Blood Transfusion Service, Helsinki, Finland
1 shared publication
Latest Publications
- 8 March 2004
- Published by Wiley in European Journal of Haematology
- Vol. 72 (4) , 268-272
Chronic thrombocytopenia of childhood: use of non‐invasive methods in clinical evaluation
Objectives : An unselected group of 21 children with chronic thrombocytopenia was investigated to understand the patients’ platelet abnormality better. Methods : Platelet counts, mean platelet volumes (MPV), membrane glycoproteins and Fcγ receptor type IIA (FcγRIIA) polymorphism H131R, reticulated platelets (%RP), antiplatelet antibodies and plasma thrombopoietin (TPO) were measured. Results : Sixteen patients had idiopathic thrombocytopenic purpura (ITP) (group 1: platelets 9/L, n = 6; group 2: 50–99 × 109/L, n = 4; group 3: 100–149 × 109/L, n = 4; group 4: splenectomised patients with normal platelet counts, n = 2). Five patients had familial thrombocytopenia. Six healthy children were studied as a reference. In the 19 thrombocytopenic patients, the platelets were significantly larger and %RP and TPO levels were significantly higher than those in the controls. Increased megakaryocytosis at diagnosis was associated with larger MPV and higher %RP but not with platelet level or TPO. The %RP was remarkably high in all ITP patients of group 1 indicating a brisk production of platelets despite low peripheral count. In all patients with familial thrombocytopenia, TPO was increased suggesting that the syndrome was not because of defective TPO production. The distribution of FcγRIIA alleles in the patients was similar to that in the controls. Conclusions : A combined application of %RP and TPO could be helpful in classifying patients with chronic thrombocytopenia into different categories. The observations may be of value in the clinical evaluation of ITP patients and lead to avoidance of invasive examinations at least in some patients.
- 8 March 2004
- Published by Wiley in European Journal of Haematology
- Vol. 72 (4) , 268-272
Chronic thrombocytopenia of childhood: use of non‐invasive methods in clinical evaluation
Objectives : An unselected group of 21 children with chronic thrombocytopenia was investigated to understand the patients’ platelet abnormality better. Methods : Platelet counts, mean platelet volumes (MPV), membrane glycoproteins and Fcγ receptor type IIA (FcγRIIA) polymorphism H131R, reticulated platelets (%RP), antiplatelet antibodies and plasma thrombopoietin (TPO) were measured. Results : Sixteen patients had idiopathic thrombocytopenic purpura (ITP) (group 1: platelets 9/L, n = 6; group 2: 50–99 × 109/L, n = 4; group 3: 100–149 × 109/L, n = 4; group 4: splenectomised patients with normal platelet counts, n = 2). Five patients had familial thrombocytopenia. Six healthy children were studied as a reference. In the 19 thrombocytopenic patients, the platelets were significantly larger and %RP and TPO levels were significantly higher than those in the controls. Increased megakaryocytosis at diagnosis was associated with larger MPV and higher %RP but not with platelet level or TPO. The %RP was remarkably high in all ITP patients of group 1 indicating a brisk production of platelets despite low peripheral count. In all patients with familial thrombocytopenia, TPO was increased suggesting that the syndrome was not because of defective TPO production. The distribution of FcγRIIA alleles in the patients was similar to that in the controls. Conclusions : A combined application of %RP and TPO could be helpful in classifying patients with chronic thrombocytopenia into different categories. The observations may be of value in the clinical evaluation of ITP patients and lead to avoidance of invasive examinations at least in some patients.
- 1 December 2003
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 25 (Supplement) , S19-S23
Platelet Function and Immune Response
Altered platelet function may cause abnormal bleeding tendency or thrombosis. The goal of this article is to provide insights for understanding how platelet functions are related to immune response. Autoantibodies and drug-induced platelet antibodies have been demonstrated to downregulate or enhance platelet function. Drug-induced immune thrombocytopenia is an important adverse effect of glycoprotein IIb/IIIa antagonists. Platelets respond to binding of glycoprotein IIb/IIIa by partial platelet activation. This includes conformational changes of glycoprotein IIb/IIIa. Membrane changes may expose immunogenic neoantigens capable of abnormally altering immune responses. The presence of drug-dependent antibodies in an unexpectedly high frequency compared with the frequency of overt thrombocytopenia has opened a model for further studies. These may include monitoring of antiplatelet immune responses when new platelet antagonists are developed and comparisons of specific immune responses in other acute thrombocytopenias, such as those induced by quinidine or heparin and that associated with gold therapy or in acute profound thrombocytopenia, which may follow vaccination with live attenuated viruses.
- 1 December 2003
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 25 (Supplement) , S19-S23
Platelet Function and Immune Response
Altered platelet function may cause abnormal bleeding tendency or thrombosis. The goal of this article is to provide insights for understanding how platelet functions are related to immune response. Autoantibodies and drug-induced platelet antibodies have been demonstrated to downregulate or enhance platelet function. Drug-induced immune thrombocytopenia is an important adverse effect of glycoprotein IIb/IIIa antagonists. Platelets respond to binding of glycoprotein IIb/IIIa by partial platelet activation. This includes conformational changes of glycoprotein IIb/IIIa. Membrane changes may expose immunogenic neoantigens capable of abnormally altering immune responses. The presence of drug-dependent antibodies in an unexpectedly high frequency compared with the frequency of overt thrombocytopenia has opened a model for further studies. These may include monitoring of antiplatelet immune responses when new platelet antagonists are developed and comparisons of specific immune responses in other acute thrombocytopenias, such as those induced by quinidine or heparin and that associated with gold therapy or in acute profound thrombocytopenia, which may follow vaccination with live attenuated viruses.
- 2 April 2003
- Published by Wiley in Vox Sanguinis
- Vol. 84 (3) , 219-227
Associations among nucleated cell, CD34+ cell and colony‐forming cell contents in cord blood units obtained through a standardized banking process
Background and Objectives Nucleated cell content is one of the main components used when evaluating cord blood (CB) units for clinical use. However, other indicators of the haematopoietic potential of a CB unit, such as CD34+ cell and colony‐forming cell (CFU‐TOT) content, have also been investigated. The aim of this study was to determine whether the CD34+ cell content could be used in selecting CB collections for banking.Materials and Methods The collection data, as well as cellular contents of 588 CB collections obtained using a standardized CB banking process, were analysed.Results Altogether, 526 CB units from the 588 collections accepted for processing were included in international search registries. The volume collected was, as expected, 69 ml (range 28–116 ml). The correlation between total CD34+ cell and CFU‐TOT (n = 88) content in the CB collection was higher (r = 0·87) than the correlation between the total nucleated cell and CFU‐TOT content (r = 0·69, both P < 0·0001). The correlations of pre‐ and postvolume reduction values of the total nucleated cell and CD34+ cell numbers were highly significant (r = 0·96, P < 0·0001, both). The total CFU‐TOT content of the CB collection correlated significantly with the total CD34+ cell content of the CB unit before cryopreservation (but after volume reduction) (r = 0·89, P < 0·0001).Conclusions CD34+ cell content predicts the haematopoietic potential of a CB unit better than nucleated cell content. Accordingly, the CD34+ cell content of CB could be used to select CB for banking purposes and for transplantation.
- 2 April 2003
- Published by Wiley in Vox Sanguinis
- Vol. 84 (3) , 219-227
Associations among nucleated cell, CD34+ cell and colony‐forming cell contents in cord blood units obtained through a standardized banking process
Background and Objectives Nucleated cell content is one of the main components used when evaluating cord blood (CB) units for clinical use. However, other indicators of the haematopoietic potential of a CB unit, such as CD34+ cell and colony‐forming cell (CFU‐TOT) content, have also been investigated. The aim of this study was to determine whether the CD34+ cell content could be used in selecting CB collections for banking.Materials and Methods The collection data, as well as cellular contents of 588 CB collections obtained using a standardized CB banking process, were analysed.Results Altogether, 526 CB units from the 588 collections accepted for processing were included in international search registries. The volume collected was, as expected, 69 ml (range 28–116 ml). The correlation between total CD34+ cell and CFU‐TOT (n = 88) content in the CB collection was higher (r = 0·87) than the correlation between the total nucleated cell and CFU‐TOT content (r = 0·69, both P < 0·0001). The correlations of pre‐ and postvolume reduction values of the total nucleated cell and CD34+ cell numbers were highly significant (r = 0·96, P < 0·0001, both). The total CFU‐TOT content of the CB collection correlated significantly with the total CD34+ cell content of the CB unit before cryopreservation (but after volume reduction) (r = 0·89, P < 0·0001).Conclusions CD34+ cell content predicts the haematopoietic potential of a CB unit better than nucleated cell content. Accordingly, the CD34+ cell content of CB could be used to select CB for banking purposes and for transplantation.
- 1 October 2001
- Published by Wiley in Clinical and Laboratory Haematology
- Vol. 23 (5) , 307-312
Glycoprotein V-specific platelet-associated antibodies in thrombocytopenic patients
In autoimmune thrombocytopenia, platelet-associated IgG (PA-IgG) frequently displays specificity against glycoprotein (GP) IIbIIIa and/or GP IbIX. Because in a high proportion of patients positive PA-IgG may not be explained by these GP specificities, studies on other target proteins are needed. We studied the presence of GP V-specific PA-IgG by direct monoclonal antibody-specific immobilization of platelet antigens (MAIPA) with the monoclonal antibody SW16. We focused on 69 consecutive random patients with histories of thrombocytopenia who were strongly positive for PA-IgG detected by the direct platelet immunofluorescence test (PIFT). PA-IgG against GP V (ratio > or = 1.5) was noted in 15 (22%) patients. The degree of PA-IgG measured by PIFT, and of GP IIbIIIa-and/or GP IbIX-specific PA-IgG measured by direct MAIPA, correlated directly with the GP V-specific PA-IgG (P < 0.001). In one patient, GP V-specific antibodies were associated with quinidine-induced thrombocytopenia. Although this patient had strongly positive GP V-specific PA-IgG, she remained negative in GP IIbIIIa- and GP IbIX-specific direct MAIPA. Two patients studied because of thrombocytopenia associated with gold therapy had strongly positive GP V-specific PA-IgG. In one patient with rheumatoid arthritis and severe gold-induced thrombocytopenia, the amount of GP V-specific PA-IgG decreased during the recovery phase. Thus, GP V may represent an important target antigen in autoimmune-mediated thrombocytopenia, especially in drug-induced thrombocytopenia.
- 1 October 2001
- Published by Wiley in Clinical and Laboratory Haematology
- Vol. 23 (5) , 307-312
Glycoprotein V-specific platelet-associated antibodies in thrombocytopenic patients
In autoimmune thrombocytopenia, platelet-associated IgG (PA-IgG) frequently displays specificity against glycoprotein (GP) IIbIIIa and/or GP IbIX. Because in a high proportion of patients positive PA-IgG may not be explained by these GP specificities, studies on other target proteins are needed. We studied the presence of GP V-specific PA-IgG by direct monoclonal antibody-specific immobilization of platelet antigens (MAIPA) with the monoclonal antibody SW16. We focused on 69 consecutive random patients with histories of thrombocytopenia who were strongly positive for PA-IgG detected by the direct platelet immunofluorescence test (PIFT). PA-IgG against GP V (ratio > or = 1.5) was noted in 15 (22%) patients. The degree of PA-IgG measured by PIFT, and of GP IIbIIIa-and/or GP IbIX-specific PA-IgG measured by direct MAIPA, correlated directly with the GP V-specific PA-IgG (P < 0.001). In one patient, GP V-specific antibodies were associated with quinidine-induced thrombocytopenia. Although this patient had strongly positive GP V-specific PA-IgG, she remained negative in GP IIbIIIa- and GP IbIX-specific direct MAIPA. Two patients studied because of thrombocytopenia associated with gold therapy had strongly positive GP V-specific PA-IgG. In one patient with rheumatoid arthritis and severe gold-induced thrombocytopenia, the amount of GP V-specific PA-IgG decreased during the recovery phase. Thus, GP V may represent an important target antigen in autoimmune-mediated thrombocytopenia, especially in drug-induced thrombocytopenia.
- 1 February 2001
- Published by Wiley in Tissue Antigens
- Vol. 57 (2) , 154-157
Platelet‐specific alloantigens in cadaveric renal transplantation. A prospective study. Effect of HPA‐5b mismatch in acute vascular rejection of renal allografts
This prospective study comprised 166 renal allograft‐recipient pairs that were studied for human platelet alloantigens (HPA) 1–3 and 5, which have been shown to be expressed by adhesion molecules of the vascular endothelium. Four of the five (80%) HPA‐5a5a regraft recipients developing acute vascular rejection (AVR) had received an HPA‐5b‐incompatible graft in contrast to one of the 32 (3%) regraft recipients without rejection. The occurrence of AVR was not explained by the degree of HLA mismatches. All four regraft recipients of an HPA‐5b‐mismatched graft with AVR were HLA‐A3,B7, and the combination of HLA‐A3 and/or B7 match and an HPA‐5b‐mismatched graft was associated with AVR. No antibodies against HPA‐5b were detected in the patients with AVR of an HPA‐5b‐mismatched graft. These preliminary findings suggest that HPA‐5b is a minor histocompatibility antigen involved in the development of AVR.
- 1 February 2001
- Published by Wiley in Tissue Antigens
- Vol. 57 (2) , 154-157
Platelet‐specific alloantigens in cadaveric renal transplantation. A prospective study. Effect of HPA‐5b mismatch in acute vascular rejection of renal allografts
This prospective study comprised 166 renal allograft‐recipient pairs that were studied for human platelet alloantigens (HPA) 1–3 and 5, which have been shown to be expressed by adhesion molecules of the vascular endothelium. Four of the five (80%) HPA‐5a5a regraft recipients developing acute vascular rejection (AVR) had received an HPA‐5b‐incompatible graft in contrast to one of the 32 (3%) regraft recipients without rejection. The occurrence of AVR was not explained by the degree of HLA mismatches. All four regraft recipients of an HPA‐5b‐mismatched graft with AVR were HLA‐A3,B7, and the combination of HLA‐A3 and/or B7 match and an HPA‐5b‐mismatched graft was associated with AVR. No antibodies against HPA‐5b were detected in the patients with AVR of an HPA‐5b‐mismatched graft. These preliminary findings suggest that HPA‐5b is a minor histocompatibility antigen involved in the development of AVR.
- 1 July 2000
- Published by Wiley in European Journal of Haematology
- Vol. 65 (1) , 66-71
Detection of reticulated platelets: estimating the degree of fluorescence of platelets stained with thiazole orange
The primary problem in the measurement of reticulated platelets (RP) stained with thiazole orange (TO) by flow cytometry is the definition of a threshold limit for fluorescence positivity. We evaluated settings for the threshold gate for TO positivity based on two principles: a fluorescence histogram (median FL1, Relative FL1) or a plot of forward light scatter (FSC; reflecting the distribution of the platelet size) versus fluorescence intensity (% RP). These methods were applied prospectively in examination of 54 healthy blood donors (16 females) and a total of 50 blinded patient samples: pregnant women with thrombocytopenia (Group 1A, n=11), thrombocytopenic women after delivery (Group 1B, n=9) and healthy women with a thrombocytopenic newborn (Group 2, n=30). Group 1A displayed higher median FL1 (mean 306, CI 279–332) as compared to that of Group 2 (mean 266, CI 255–277; p=0.0038) or to that of the female controls (mean 249, CI 231–268; pp=0.037). When analysing the % RP, the difference between these groups was not significant. In the patients (n=50), the median FSC (mean 407, SD 40, CI 395–418) was also higher than that of the controls (n=54; mean 383, SD 25, CI 376–390; Mann–Whitney U‐test, p=0.0015). In Group 1A, a significant correlation was observed between the Patient median FL1 and Patient median FSC (r=0.62, p=0.043). When developing methods for the measurement of RP, it seems to be useful to analyse the data with more than one principle to define the threshold limit for TO positivity.
- 1 July 2000
- Published by Wiley in European Journal of Haematology
- Vol. 65 (1) , 66-71
Detection of reticulated platelets: estimating the degree of fluorescence of platelets stained with thiazole orange
The primary problem in the measurement of reticulated platelets (RP) stained with thiazole orange (TO) by flow cytometry is the definition of a threshold limit for fluorescence positivity. We evaluated settings for the threshold gate for TO positivity based on two principles: a fluorescence histogram (median FL1, Relative FL1) or a plot of forward light scatter (FSC; reflecting the distribution of the platelet size) versus fluorescence intensity (% RP). These methods were applied prospectively in examination of 54 healthy blood donors (16 females) and a total of 50 blinded patient samples: pregnant women with thrombocytopenia (Group 1A, n=11), thrombocytopenic women after delivery (Group 1B, n=9) and healthy women with a thrombocytopenic newborn (Group 2, n=30). Group 1A displayed higher median FL1 (mean 306, CI 279–332) as compared to that of Group 2 (mean 266, CI 255–277; p=0.0038) or to that of the female controls (mean 249, CI 231–268; pp=0.037). When analysing the % RP, the difference between these groups was not significant. In the patients (n=50), the median FSC (mean 407, SD 40, CI 395–418) was also higher than that of the controls (n=54; mean 383, SD 25, CI 376–390; Mann–Whitney U‐test, p=0.0015). In Group 1A, a significant correlation was observed between the Patient median FL1 and Patient median FSC (r=0.62, p=0.043). When developing methods for the measurement of RP, it seems to be useful to analyse the data with more than one principle to define the threshold limit for TO positivity.
- 1 January 2000
- Vol. 116 (13) , 1345-6
[Stem cells from the umbilical cord blood].
- 1 May 1999
- Published by Wiley in Haemophilia
- Vol. 5 (s2) , 72-74
von Willebrand disease in Finland
The Finnish Red Cross Blood Transfusion Service has served as the national reference laboratory for haemostasis for more than 40 years and remains still the only one in the country to diagnose inherited coagulation factor deficiencies. By September 1997, 1076 patients with von Willebrand disease (vWD) were registered. The severity of bleeding symptoms leading to diagnosis varied according to the type of vWD. After prepubertal phase distinctly more female than male patients were diagnosed. The prevalence of severe type 3 vWD is 4:1 000 000.
- 1 May 1999
- Published by Wiley in Haemophilia
- Vol. 5 (s2) , 72-74
von Willebrand disease in Finland
The Finnish Red Cross Blood Transfusion Service has served as the national reference laboratory for haemostasis for more than 40 years and remains still the only one in the country to diagnose inherited coagulation factor deficiencies. By September 1997, 1076 patients with von Willebrand disease (vWD) were registered. The severity of bleeding symptoms leading to diagnosis varied according to the type of vWD. After prepubertal phase distinctly more female than male patients were diagnosed. The prevalence of severe type 3 vWD is 4:1 000 000.
- 24 April 1999
- Published by Wiley in European Journal of Haematology
- Vol. 62 (4) , 256-264
Variant Bernard‐Soulier syndrome due to homozygous Asn45Ser mutation in the platelet glycoprotein (GP) IX in seven patients of five unrelated Finnish families
Bernard‐Soulier syndrome (BSS), a rare bleeding disorder with macrothrombocytopenia, is caused by a defect of the platelet glycoprotein (GP) Ib/IX/V complex. Here we report a variant form of BSS in eleven patients of five unrelated families who originate from a particular area of Finland. The differential diagnosis from idiopathic thrombocytopenic purpura was difficult. Bleeding symptoms were epistaxis and haematomas debuting in childhood, but no spontaneous, severe bleeding episodes were reported. The platelet count varied from 43 to 81 × 109/l. Screening the entire GP Ibα, GP Ibβ, GP IX and GP V genes revealed a recurrent homozygous Asn45Ser mutation in GP IX in all probands. Flow cytometry showed markedly reduced expression of GP Ib (<10%), and only moderately reduced expression of GP IX (24–36%) and GP V (38–49%). The expression of subunits seemed to vary independently from the normal polymorphisms. Heterozygotes did not differ significantly from controls by their GP Ib/IX/V expression. Since the Asn45Ser mutation has also been reported in three other kindreds of northern and central European origin, this study reveals that instead of being a mutation hot spot, it may be ancient and scattered in Europe. Moderate, chronic thrombocytopenia should be carefully studied to diagnose variant BSS correctly from treatment resistant idiopathic thrombocytopenia.
- 24 April 1999
- Published by Wiley in European Journal of Haematology
- Vol. 62 (4) , 256-264
Variant Bernard‐Soulier syndrome due to homozygous Asn45Ser mutation in the platelet glycoprotein (GP) IX in seven patients of five unrelated Finnish families
Bernard‐Soulier syndrome (BSS), a rare bleeding disorder with macrothrombocytopenia, is caused by a defect of the platelet glycoprotein (GP) Ib/IX/V complex. Here we report a variant form of BSS in eleven patients of five unrelated families who originate from a particular area of Finland. The differential diagnosis from idiopathic thrombocytopenic purpura was difficult. Bleeding symptoms were epistaxis and haematomas debuting in childhood, but no spontaneous, severe bleeding episodes were reported. The platelet count varied from 43 to 81 × 109/l. Screening the entire GP Ibα, GP Ibβ, GP IX and GP V genes revealed a recurrent homozygous Asn45Ser mutation in GP IX in all probands. Flow cytometry showed markedly reduced expression of GP Ib (<10%), and only moderately reduced expression of GP IX (24–36%) and GP V (38–49%). The expression of subunits seemed to vary independently from the normal polymorphisms. Heterozygotes did not differ significantly from controls by their GP Ib/IX/V expression. Since the Asn45Ser mutation has also been reported in three other kindreds of northern and central European origin, this study reveals that instead of being a mutation hot spot, it may be ancient and scattered in Europe. Moderate, chronic thrombocytopenia should be carefully studied to diagnose variant BSS correctly from treatment resistant idiopathic thrombocytopenia.
- 1 January 1996
- Vol. 112 (5) , 412-6
[Heparin induced thrombocytopenia and thrombosis].